Arare disease is a disease that affects a small percentage of the population. In some parts of the world, the term orphan disease describes a rare disease whose rarity results in little or no funding or research for treatments, without financial incentives from governments or other agencies. Orphan drugs are medications targeting orphan diseases.
Most rare diseases are genetic in origin and thus are present throughout the person's entire life, even if symptoms do not immediately appear. Many rare diseases appear early in life, and about 30% of children with rare diseases will die before reaching their fifth birthdays.[1] With only four diagnosed patients in 27 years, ribose-5-phosphate isomerase deficiency is considered the 2nd rarest known genetic disease being beaten only by Fields Condition affecting two known individuals, Catherine and Kirstie Fields.[2][3]
No single number has been agreed upon for which a disease is considered rare. Global Genes has estimated that currently approximately 10,000 rare diseases exist globally, with 80% of these having identified genetic origins.[4]
There is no single, widely accepted definition for rare diseases. Some definitions rely solely on the number of people living with a disease, and other definitions include other factors, such as the existence of adequate treatments or the severity of the disease.
In the United States, the Rare Diseases Act of 2002 defines rare disease strictly according to prevalence, specifically "any disease or condition that affects fewer than 200,000 people in the United States",[5] or about 1 in 1,500 people. This definition is essentially the same as that of the Orphan Drug Act of 1983, a federal law that was written to encourage research into rare diseases and possible cures.
In Japan, the legal definition of a rare disease is one that affects fewer than 50,000 patients in Japan, or about 1 in 2,500 people.[6]
However, the European Commission on Public Health defines rare diseases as "life-threatening or chronically debilitating diseases which are of such low prevalence that special combined efforts are needed to address them".[7] The term low prevalence is later defined as generally meaning fewer than 1 in 2,000 people.[8] Diseases that are statistically rare, but not also life-threatening, chronically debilitating, or inadequately treated, are excluded from their definition.
The definitions used in the medical literature and by national health plans are similarly divided, with definitions ranging from 1/1,000 to 1/200,000.[6]
| Country | Patient ratio as defined | Patient ratio standardised for comparison |
|---|---|---|
| Brazil | 65 in 100,000 | 1 in 1,538 |
| United States | <200,000 in population[5] | 1 in 1,659 |
| Argentina | 1 in 2,000 | 1 in 2,000 |
| Australia | 5 in 10,000 | 1 in 2,000 |
| Chile | 5 in 10,000 | 1 in 2,000 |
| Colombia | 1 in 2,000 | 1 in 2,000 |
| European Union | 5 in 10,000 | 1 in 2,000 |
| Mexico | 5 in 10,000 | 1 in 2,000 |
| Norway | 5 in 10,000 | 1 in 2,000 |
| Panama | 1 in 2,000 | 1 in 2,000 |
| Singapore | 1 in 2,000 | 1 in 2,000 |
| Switzerland | 5 in 10,000 | 1 in 2,000 |
| United Kingdom | 1 in 2,000[10] | 1 in 2,000 |
| Japan | <50,000 in population[6] | 1 in 2,507 |
| Russian Federation | 10 in 100,000 | 1 in 10,000 |
| Peru | 1 in 100,000 | 1 in 100,000 |
Because of definitions that include reference to treatment availability, a lack of resources, and severity of the disease, the term orphan disease is frequently used as a synonym for rare disease.[6] But in the United States and the European Union, "orphan diseases" have a distinct legal meaning.
The United States' Orphan Drug Act includes both rare diseases and any non-rare diseases "for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for such disease or condition will [be] recovered from sales in the United States of such drug" as orphan diseases.[11]
The European Organization for Rare Diseases (EURORDIS) also includes both rare diseases and neglected diseases into a larger category of "orphan diseases".[12]
Prevalence (number of people living with a disease at a given moment), rather than incidence (number of new diagnoses in a given year), is used to describe the impact of rare diseases. The Global Genes Project estimates some 300 million people worldwide are affected by a rare disease.
The European Organization for Rare Diseases (EURORDIS) estimates that between 3.5 and 5.9% of the world's population is affected by one of approx. 6,000 distinct rare diseases identified to-date.[13] European Union has suggested that between 6 and 8% of the European population could be affected by a rare disease sometime in their lives.[14]
About 80% of rare diseases have a genetic component and only about 400 have therapies, according to Rare Genomics Institute.[15]
Rare diseases can vary in prevalence between populations, so a disease that is rare in some populations may be common in others. This is especially true of genetic diseases and infectious diseases. An example is cystic fibrosis, a genetic disease: it is rare in most parts of Asia but relatively common in Europe and in populations of European descent. In smaller communities, the founder effect can result in a disease that is very rare worldwide being prevalent within the smaller community. Many infectious diseases are prevalent in a given geographic area but rare everywhere else. Other diseases, such as many rare forms of cancer, have no apparent pattern of distribution but are simply rare. The classification of other conditions depends in part on the population being studied: All forms of cancer in children are generally considered rare,[16] because so few children develop cancer, but the same cancer in adults may be more common.
Estimating the incidence and prevalence of rare diseases is a complex process due to their wide range of prevalence rates. Rare diseases with higher prevalences can be estimated through a screening panel or patient registries, while diseases which are exceedingly rare may only be able to be estimated through a multi-step nationwide reporting process or case reports. Therefore, the data is often incomplete and complex to amalgamate, compare, and update continually. The Genetic and Rare Diseases Information Center at the National Center for Advancing Translational Sciences curates and compiles rare disease prevalence and incidence from PubMed articles and abstracts using a combination of deep learning algorithms and rare disease experts.[17]
About 40 rare diseases have a far higher prevalence in Finland; these are known collectively as Finnish heritage disease. Similarly, there are rare genetic diseases among the Amish religious communities in the US and among ethnically Jewish people.
A rare disease is defined as one that affects fewer than 200,000 people across a broad range of possible disorders.[18] Chronic genetic diseases are commonly classified as rare.[18][19] Among numerous possibilities, rare diseases may result from bacterialorviral infections, allergies, chromosome disorders, degenerative and proliferative causes, affecting any body organ.[18] Rare diseases may be chronic or incurable, although many short-term medical conditions are also rare diseases.[18]
The NIH's Office of Rare Diseases Research (ORDR) was established by H.R. 4013/Public Law 107–280 in 2002.[20] H.R. 4014, signed the same day, refers to the "Rare Diseases Orphan Product Development Act".[21] Similar initiatives have been proposed in Europe.[22] The ORDR also runs the Rare Diseases Clinical Research Network (RDCRN). The RDCRN provides support for clinical studies and facilitating collaboration, study enrollment and data sharing.[23]
In 2013, the United Kingdom government published The UK Strategy for Rare Diseases which "aims to ensure no one gets left behind just because they have a rare disease", with 51 recommendations for care and treatment across the UK to be implemented by 2020.[24] Health services in the four constituent countries agreed to adopt implementation plans by 2014, but by October 2016, the Health Service in England had not produced a plan and the all-party parliamentary group on Rare, Genetic and Undiagnosed Conditions produced a report Leaving No One Behind: Why England needs an implementation plan for the UK Strategy for Rare Diseases in February 2017.[25] In March 2017 it was announced that NHS England would develop an implementation plan.[26] In January 2018 NHS England published its Implementation Plan for the UK Strategy for Rare Diseases.[27] In January 2021 the Department of Health and Social Care published the UK Rare Diseases Framework, a policy paper which included a commitment that the four nations would develop action plans, working with the rare disease community, and that "where possible, each nation will aim to publish the action plans in 2021".[28] NHS England published England Rare Diseases Action Plan 2022 in February 2022.[29]
Organisations around the world are exploring ways of involving people affected by rare diseases in helping shape future research, including using online methods to explore the perspectives of multiple stakeholders.[30]
Rare Disease Day is held in Europe, Canada, the United States, and India on the last day of February (thus, in leap years, on February 29, the rarest day)[31] to raise awareness for rare diseases.[32][33][34][35] There are a number of non-profit and charitable organisations which push for further awareness, interest, and engagement in the subject of rare diseases, including EURORDIS, Genetic Alliance UK, and the Rare Revolution Magazine.[36]
chosen because 29 February is the rarest day of the year
| International |
|
|---|---|
| National |
|
